Source: Annual Congress 2003 - Newer and alternative non-steroidal treatments for asthmatic inflammation
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Bousquet, R. Niven, G. Ayre, H. Fox, M. Blogg (Montpellier, France; Manchester, Horsham, United Kingdom). Efficacy of omalizumab in patients with moderate-to-severe allergic asthma that is poorly controlled on GINA (1998) treatment step 3 or 4. Eur Respir J 2003; 22: Suppl. 45, 1389

Member's Comments

No comment yet.

Related content which might interest you: Reslizumab (RES) in asthma patients (pts) with severe eosinophilic asthma stratified by GINA asthma steps 4 and 5: Analysis of two phase 3, placebo (PBO)-controlled trials Source: International Congress 2016 – Asthma management Year: 2016 10 Year evaluation of patients with severe uncontrolled allergic asthma treated with Omalizumab. Source: International Congress 2018 – Physiological and biological insights in asthma Year: 2018 Long-term effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: Real-life data from 3 UK centres Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012 Omalizumab reduces asthma exacerbations in children (6–<12 years) with moderate-to-severe allergic (IgE-mediated) asthma irrespective of baseline LABA use Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009 ‘Real-life‘ persistence beyond the first year of omalizumab treatment in patients with severe allergic asthma: The R-Pixel study Source: Annual Congress 2011 - Asthma management and response Year: 2011 Anti-IgE: lessons from clinical trials in patients with severe allergic asthma symptomatic despite optimised therapy Source: Eur Respir Rev 2007; 16: 73-77 Year: 2007 Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: Pooled data from 4 UK centres Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012 Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: Pooled data from 3 UK centres Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E Year: 2011 Anti-IgE therapy with omalizumab decreases exacerbations in patients with poorly controlled moderate-to-severe allergic asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003 Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with medium-dose ICS/LABA therapy (on GINA step 4) prior to study entry: Results from IRIDIUM study Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021 Cost-effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: adaptation of INNOVATE and ETOPA data to the Netherlands Source: Annual Congress 2007 - Cost-effectiveness in diagnosis, therapy and care Year: 2007 Persistency of treatment response to omalizumab in patients with severe allergic (IgE-mediated) asthma Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with high-dose ICS/LABA therapy (on GINA step 5) prior to study entry: Results from IRIDIUM study Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021 Stratification of eosinophilic asthma patients treated with reslizumab and GINA Step 4 or 5 therapy Source: ERJ Open Res, 3 (3) 00004-2017; 10.1183/23120541.00004-2017 Year: 2017 Characteristics of the uncontrolled asthmatic patients on GINA step 4 treatment in Korea Source: Annual Congress 2012 - Epidemiology of asthma Year: 2012 Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma at a single UK hospital Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Omalizumab (Xolair®) reduces exacerbations in adolescents more than in adults with allergic (IgE-mediated) asthma: a subgroup analysis of pooled clinical trials Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008 Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Which patients should be treated with anti-IgE? Source: Eur Respir Rev 2007; 16: 85-87 Year: 2007